Frontiers in oncology · 2025
A phase I study of S-1 and cisplatin with concurrent hypofractionated carbon-ion radiotherapy for patients with stage III non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miura Yosuke, Kubo Nobuteru, Sunaga Noriaki, Okano Naoko, Tsurumaki Hiroaki, Kawamura Hidemasa, Sakurai Reiko, Maeno Toshitaka, Hisada Takeshi, Ohno Tatsuya
Аннотация
OBJECTIVES: We conducted a phase I study to evaluate the recommended dose of S-1 in combination with cisplatin (SP) and concurrent carbon ion radiotherapy (CIRT) in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC).
MATERIALS AND METHODS: S-1 was administered orally twice daily after a meal for 14 consecutive days, and cisplatin was administered on days 1 and 8. The dose of each drug in this study was planned as follows: level 0, S-1-30 mg/m2 twice daily and cisplatin 40 mg/m2; level 1, S-1-40 mg/m2 twice daily and cisplatin 40 mg/m2. CIRT was conducted at a total dose of 64 Gy (relative biological effectiveness) in 16 fractions.
RESULTS: Six patients were enrolled in this study. At level 1, one patient experienced grade 3 elevated alanine aminotransferase and aspartate aminotransferase levels, which is regarded as a dose-limiting toxicity. This event improved immediately. Five patients developed grade 2 esophagitis. In three of the five patients, symptoms such as pain and dysphagia due to esophagitis recurred several months after resolution of the acute esophagitis that occurred during irradiation. None of the patients experienced adverse events of ≥grade 3. Thus, level 1 was determined to be the recommended dose.
CONCLUSION: Chemotherapy with SP and concurrent CIRT is feasible and well-tolerated in patients with Stage III LA-NSCLC.
MATERIALS AND METHODS: S-1 was administered orally twice daily after a meal for 14 consecutive days, and cisplatin was administered on days 1 and 8. The dose of each drug in this study was planned as follows: level 0, S-1-30 mg/m2 twice daily and cisplatin 40 mg/m2; level 1, S-1-40 mg/m2 twice daily and cisplatin 40 mg/m2. CIRT was conducted at a total dose of 64 Gy (relative biological effectiveness) in 16 fractions.
RESULTS: Six patients were enrolled in this study. At level 1, one patient experienced grade 3 elevated alanine aminotransferase and aspartate aminotransferase levels, which is regarded as a dose-limiting toxicity. This event improved immediately. Five patients developed grade 2 esophagitis. In three of the five patients, symptoms such as pain and dysphagia due to esophagitis recurred several months after resolution of the acute esophagitis that occurred during irradiation. None of the patients experienced adverse events of ≥grade 3. Thus, level 1 was determined to be the recommended dose.
CONCLUSION: Chemotherapy with SP and concurrent CIRT is feasible and well-tolerated in patients with Stage III LA-NSCLC.